Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Double-blind, Randomized, Multi-site, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Immunogenicity of Intramuscular HIL-214 Norovirus Vaccine in Healthy Children 5 Months of Age at Initial Vaccination

NCT05281094 is registered in ClinicalTrials.gov with HilleVax as lead sponsor.

NCT NCT05281094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05281094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Double-blind, Randomized, Multi-site, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Immunogenicity of Intramuscular HIL-214 Norovirus Vaccine in Healthy Children 5 Months of Age at Initial Vaccination
Lead sponsor
HilleVax
Phase
Phase 2/3
Overall status
Terminated
Start date
April 28, 2022
Completion date
September 30, 2024
Enrollment
3,084 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteritis